MarginsXMarginsX
Home › Markets › Health Care › GALT

Galectin Therapeutics Inc. (GALT)

GALT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.02
-0.98% on the day
Market cap
$305.2M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerGALT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001133416
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
10.0 months
$13.3M cash at June 30, 2026
Share count, 1 year
+57.4%
2025-08-07 to 2026-08-06 · +69.3% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
-$6.4M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements."
10-Q 2026-08-14
Cash and burn$13.3M cash; operating cash flow -$4.0M a quarter.Report 2026-06-30
Shares outstanding100,849,644 (2026-08-06); 64,060,262 a year earlier; 59,582,253 three years earlier.Cover page 2026-08-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-03-31
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCherry Bekaert LLP, Atlanta, Georgia, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $23K, sold $6.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$9.1M-$2.4M$13.3MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$5.0M-$3.9M$14.1MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q4 2025
2025-12-31
Not filed-$5.5M-$6.0M$17.7MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$8.2M-$3.5M$11.5MNo debt tagsNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed-$7.5M-$6.6M$13.8MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$9.6M-$7.7M$7.4MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q4 2024
2024-12-31
Not filed-$12.0M-$12.8M$15.1MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$11.2M-$8.5M$27.1MNo debt tagsNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-03-31
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-10-13

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.9%
1 month-17.3%
3 months-13.6%
Year to date-26.7%
1 year-44.8%
From 52-week high-53.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ALTAltimmune Inc.$1.56-5.17%$303.6M
BNTCBenitec Biopharma Inc.$8.54-5.53%$308.5M
ENTAEnanta Pharmaceuticals Inc.$10.67-2.91%$310.8M
LRMRLarimar Therapeutics Inc.$3.00-0.66%$311.6M
EBSEmergent BioSolutions Inc.$5.81+0.35%$298.7M
EVMNEvommune Inc.$7.10-6.95%$293.6M
FULCFulcrum Therapeutics Inc.$3.71-1.59%$283.4M
AVIRAtea Pharmaceuticals Inc.$4.12-4.19%$330.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier